Physician profile
Kellie Wendzinski
NPI 1710500640
$1,416.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $495 · 2022: $579 · 2023: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $361.34 | 2021-2022 | |
| Amgen INC. | $250.85 | 2021-2022 | |
| Novo Nordisk INC | $134.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $128.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2023 | Eliquis |
| Grifols USA, LLC | $124.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.57 | 2022 | |
| Merck Sharp & Dohme LLC | $45.16 | 2022-2023 | Vaxelis, Gardasil 9, M-M-R II |
| Organon LLC | $43.18 | 2023 | Nexplanon |
| Abbvie INC. | $30.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.78 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2022 | |
| Avanos Medical | $14.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2022 | |
| Horizon Therapeutics Plc | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Wendzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.